This bill, known as the lead poisoning prevention and treatment act of 2024, mandates that health insurance coverage for blood lead testing should not be subject to a co-payment, deductible, or coinsurance. It further stipulates that insurance coverage must include follow-up blood lead testing necessary for completing preventive screening when initial testing shows an elevated blood lead level or is inconclusive. The bill amends RSA 415:6-v and RSA 415:18-aa to reflect these changes, ensuring that benefits for blood lead testing are not subject to greater cost-sharing than other similar benefits provided by the insurer.

The legal language inserted into the current law specifies that benefits for blood lead testing, including necessary follow-up tests, shall be covered without additional cost-sharing. The deletions from the current law remove the allowance for greater co-payment, deductible, or coinsurance for blood lead testing compared to other medical benefits. The act is set to take effect 60 days after its passage, with an approved date of July 03, 2024, and an effective date of September 01, 2024.

Statutes affected:
Introduced: 415:6-v, 415:18-aa
As Amended by the Senate: 415:6-v, 415:18-aa
Version adopted by both bodies: 415:6-v, 415:18-aa
CHAPTERED FINAL VERSION: 415:6-v, 415:18-aa